Clinical Topics

Articles

Five years after bariatric surgery for uncontrolled T2D patients reported improvements in physical health and QoL but measures of psychosocial wellbeing remained flat. 

In Patients with Uncontrolled T2D, Bariatric Surgery Associated with Long-term Improvement in Physical Domains, Diabetes-related QoL 

Slideshows

Methods proven to prevent ASCVD may fall short in certain populations if the impacts of SDOH are not closely monitored. The ACC/AHA provide considerations for 7 health domains.

Social Determinants of Health and ASCVD Prevention: Clinical  Considerations 

From obesity to pneumococcal disease, we have picked the top 6 FDA-approved drugs every primary care physician should know about from the second quarter. 

6 New Drugs Approved for Primary Care: Q2 2021

Podcasts

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with obesity specialist, Sandra Christensen, MSN, ARNP.

Primary Viewpoints Episode 10: Weight Bias in Health Care: What Needs to be Done?

Videos

Diabetes investigator John Buse, MD, PhD, says laser focus on reducing T2D risk factors is equally as important as using the next right drug against the disease. 

At ADA 2021, John Buse, MD, PhD, says US Must Focus on Control of Obesity, Other T2D Risk Factors 

Dr Buse’s in-depth review of the GRADE study is followed by a discussion of the keen need for more comparative research and the many new questions the results have raised about optimal T2D therapy. 

Inside GRADE: Exec Committee Member John Buse, MD, PhD, Toplines Study Results, Calls for More Head-to-Head Research  

The much anticipated results from the SURPASS 2 clinical trial demonstrated reductions in A1c and body weight with tirzepatide that were significant and superior to those with semaglutide. 

Novel Agent Tirzepatide Superior to Semaglutide in Reducing A1c, Body Weight in Type 2 Diabetes 

STEP program investigator Robert F. Kushner, MD, reviews the "unprecedented" clinical trial results for semaglutide 2.4 mg and speaks specifically to primary care clinicians treating obesity.  

Semaglutide 2.4 mg for Obesity: Investigator Toplines Clinical Trial Results, Focused on Primary Care

Review of more than 300 clinical trials with products purported to facilitate weight loss found wide variability in risk of bias and data sufficiency suggesting caution among patients and physicians.  

High-quality Evidence Minimal for Supplements, Alternative Therapies Claiming Weight Loss Support

It is critical for physicians to urge patients with obesity to get vaccinated against COVID-19 as they are one of the highest risk patient populations. 